ArticleAnalytical biochemistry2026
Efficient tag-less purification of recombinant human tau proteins.
Article in Analytical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Protocol for efficient purification of endotoxin-free human recombinant tau protein.STAR protocols · 2026Article
- Lysine methylation is an endogenous post-translational modifications of tau protein in human brain and a modulator of aggregation propensity.Methods in enzymology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Tau proteins normally function as part of the neuronal cytoskeleton but aggregate to form filamentous inclusions in tauopathies such as Alzheimer's disease. The diverse functions of tau protein are frequently interrogated using biochemical assays that require highly purified tau as substrate. Conventional recombinant tau purification leverages polyhistidine (His6) tags to enable rapid and efficient isolation through immobilized metal affinity chromatography (IMAC). Preparation of native tau by this approach requires removal of His6 tags through additional processing steps. Here we report a protocol for purifying native recombinant full-length tau protein that retains the speed, convenience, broad availability and scalability of IMAC while eliminating the need for post-purification proteolytic cleavage. The method has been validated across a wide array of tau constructs, including full-length isoforms, missense mutants, and a truncation construct containing an aggregation-prone region of the microtubule-binding domain. Owing to its scalability and reproducibility, the method is well suited for structure-activity relationship investigations involving curated tau variant libraries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.